Coat protein-mediated resistance to TMV infection of Nicotiana tabacum involves multiple modes of interference by coat protein  by Bendahmane, Mohammed et al.
7) 107–116
www.elsevier.com/locate/yviroVirology 366 (200Coat protein-mediated resistance to TMV infection of Nicotiana tabacum
involves multiple modes of interference by coat protein
Mohammed Bendahmane a,b, Iju Chen a, Sebastian Asurmendi a,c, Ariel Alejandro Bazzini a,c,
Judit Szecsi a,d, Roger N. Beachy a,⁎
a Donald Danforth Plant Science Center, 975 N. Warson Rd., St. Louis, MO 63132, USA
b Reproduction et Développement des Plantes UMR5667-INRA-CNRS-UCBL, Ecole Normale Supérieure, 46 allée d’Italie 69364 Lyon cedex 07, France
c Instituto de Biotecnología, INTA Castelar, Los Reseros y Las Cabañas S/N, B1712WAA, Buenos Aires, Argentina
d EVIR, INSERM 758, ENS, 46 allée d’Italie 69364 Lyon cedex 07, France
Received 24 January 2007; returned to author for revision 13 February 2007; accepted 8 March 2007
Available online 11 May 2007Abstract
Expression of tobacco mosaic virus (TMV) coat protein (CP) restricts virus disassembly and alters the accumulation of the movement protein
(MP). To characterize the role of structure of transgenic CP in regulating virus disassembly and production of MP, we generated CPs with
mutations at residues Glu50 and Asp77, located in the interface between juxtaposed CP subunits. In transgenic Nicotiana tabacum and BY-2 cells,
three categories of coat protein-mediated resistance (CP-MR) levels were identified: wild-type CP-MR; elevated CP-MR; and no CP-MR. Mutant
CPs that interfered with the accumulation of virus replication complexes conferred very high levels of protection to TMV, except by CPE50D which
provided no protection in the systemic host (Xanthi-nn) but high CP-MR in the local lesion host (Xanthi-NN). In transgenic BY-2 cells CPE50D
strongly reduced accumulation of MP:GFP. In general, there was a strong correlation between the capacity for CP to assemble to pseudovirions
and CP-MR, while there was not strong correlation with packaging viral RNA and CP-MR. The data demonstrate that interference with one or
more steps in virus infection and replication by wild type and mutant CP determine the degree of CP-MR.
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The structural proteins of plant viruses have evolved to self-
associate into complex macromolecules that are centrally
involved in virus biology. The structural and biophysical
properties of tobacco mosaic virus (TMV; type member of the
genus Tobamovirus) coat protein (CP) have been widely used to
study the role of macromolecular assembly in the biology of
virus–host interactions, in particular in host resistance and
disease development. The TMV genome encodes at least four
proteins: the 126-kDa and 183-kDa replicase proteins, the
30-kDa cell-to-cell movement protein (MP), and the 17.5-kDa⁎ Corresponding author. Fax: +1 314 587 1964.
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doi:10.1016/j.virol.2007.03.052CP. The MP and CP are encoded by subgenomic RNAs that are
co-terminal with the 3′ end of virion RNA (Goelet et al., 1982).
The CP can elicit specific host resistance in transgenic plants
(coat protein-mediated resistance; CP-MR). Other studies indi-
cate that the three-dimensional structure of CP is critical to the
control of these responses, either directly through specific
structural motifs or indirectly via alterations in CP assembly and
disassembly processes (for more details, see the review by
Culver (2002)).
TMV particles are highly stable in vitro. Upon entry into a
cell, however, disassembly of virions proceeds very rapidly via
a process that involves virion destabilization that likely results
from repulsion between carboxyl–carboxylate groups on amino
acids (a.a.) at residues 50 (glutamic acid; Glu, E) and 77
(aspartic acid; Asp, D). These a.a. are located on the interface
between adjacent and juxtaposed CP subunits. In the extra-
cellular environment, the negatively charged carboxylate
groups are stabilized by cations, such as Ca2+ ions or protons
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revealed inter-subunit carboxylate interactions at three locations
within the virus (Namba and Stubbs, 1986), including the
interaction of Glu50 from one subunit with Asp77 of the subunit
below (Fig. 1).
Coat protein-mediated resistance (CP-MR) refers to the
resistance of transgenic plants that produce CP to the virus from
which the CP gene is derived (Powell-Abel et al., 1986).
Despite extensive studies, the molecular mechanisms that
govern CP-MR are not fully understood; furthermore, mechan-
isms of CP-MR are different for different viruses. In the case of
CP-MR against TMV, the CP interferes with virus disassembly
(reviewed by Bendahmane and Beachy, 1999). Bendahmane et
al. (1997) showed that mutant CPs that lack the ability to
aggregate failed to protect against TMV infection, whereas a CP
with increased aggregation, e.g., Thr42Trp (CPT42W), provided
higher levels of protection than did wild type (w.t.) CP. These
results established a direct correlation between the capacity for
CP self-assembly and CP-MR. These findings were later
confirmed by Lu et al. (1998) using similar and also different
mutant CPs expressed via a PVX transient expression vector.
One of the mutants designed to remove repulsive inter-subunit
carboxylate interaction between E50 and D77, namely mutant
CP-E50Q/D77N, was shown to stabilize CP–CP interactions
and to provide significantly higher levels of CP-MR as
compared to wild-type CP (Lu et al., 1998). Subsequently,
Bendahmane et al. (2002) reported that w.t. CP can have aFig. 1. (A) Ribbon representation of the alpha-carbon backbone of two CP
subunits belonging to two superimposed helical turns of TMV virion. The N and
C termini located at the outer radius of the virus are indicated. The position of
the interacting carboxylate residues Glu50 and Asp77 and of the Thr42 residue
is shown. (B) Computer graphic representation of two and half virion helical
turns of CP subunits. The N-terminus and the C-terminus of the CPmolecules lie
on the external surface of the assembled subunits.positive effect on the production of MP and, thereby, on virus
replication and cell to cell movement. Other experiments
showed that CPT42W interferes with normal function of w.t. CP
and has a negative effect on MP accumulation (Bendahmane et
al., 2002) that reduces the formation of virus replication
complexes (Asurmendi et al., 2004). This in turn restricts cell–
cell spread of infection and increases the efficacy of CP-MR. A
mutant of CP that did not assemble, CPT28W, did not restrict
production of VRCs (Virus Replication Complexes) or provide
CP-MR.
In the present study, we applied knowledge of the atomic
structure of TMV CP to generate mutant CPs that target the
inter-subunit carboxyl–carboxylate interactions between Glu50
and Asp77 residues. The mutant CPs were then tested in virus
infection and CP-MR assays. We show that CP-MR to TMV
involves at least two independent mechanisms: (i) interference
by transgenic CP with disassembly of challenge virus; and (ii)
interference of transgenic CP with formation of replication
complexes, thus interfering with virus movement. We propose
that the degree of regulation of replication by aggregates of CP
determines the relative strength of CP-MR that is conferred by
w.t. and mutant CP.
Results
Effects of mutants of CP on virus biology
The known atomic structure of the TMV CP (Namba et al.,
1989) was used to select for mutation amino acids (a.a.) that are
important for CP subunit interactions. Interactions between
carboxylate groups between Glu50 and Asp77 (Fig. 1; located
in RS and RR alpha-helices, respectively; Namba et al., 1989)
result in repulsion of axially adjacent subunits. It was proposed
that repulsion of these amino acids play an important role in
TMV disassembly (Culver et al., 1995; Lu et al., 1996). The
removal or change of inter-subunit interactions is expected to
enhance or reduce the stability of aggregates of CP molecules
(depending upon the mutation) due to effects on the axially
adjacent turns of the helix that forms as virus and virus-like
particles (VLPs) are assembled. Ten amino acid substitutions
were created to disrupt the specific carboxyl–carboxylate inter-
CP subunit interactions between Glu50 and Asp77. The amino
acids substitutions that created four types of mutations (see
bellow) are expected to interfere with normal quaternary
structure of CP subunits but not with its ternary structure.
Effects on virus assembly
Mutant CPs were examined for their ability to form VLPs
following infection of tobacco leaves with virus constructs that
contain mutant CP (Table 1). All virus mutants produced CP
molecules indicating that mutations did not completely abolish
virus replication or CP accumulation (data not shown). Electron
microscopy studies revealed that all infections produced VLPs
(Fig. 2) indicating that the mutations did not affect self-
assembly of the CP. However, most mutants failed to produce
VLPs of the size of w.t. TMV (i.e.,∼300 nm); this indicates that
selected mutations affected virion or VLP stability.
Table 1
Summary showing the effect of mutations in TMV CP at amino acids Thr28, Thr42, Glu50 and Asp77
VLPs a Virus systemic movement
in Xanthi-nn b
CP-MR against TMV in transgenic
Xanthi-NN
(local lesions) c
Xanthi-nn
(Fig. 3) d
CP w.t. Virion Yes 99% W.t. CP-MR
CPE50K VLPs (long rods) Yes e 90–96% Equal to w.t. CP-MR
CPE50R VLPs(long rods) Delayed 99–99.4% Equal to w.t. CP-MR
CPD77N VLPs (short rods) Delayed 99–100% Equal to w.t. CP-MR
CPT42W f Highly stable VLP No 96–99% Better than w.t. CP-MR
CPD77R VLPs (long rods) Yes 96–98% Better than w.t. CP-MR
CPE50M VLPs (W.t.) Yes 99.8–100% Better than w.t. CP-MR
CPD77E VLPs (long rods) Yes 98.6–99.4% Better than w.t. CP-MR
CPD77A VLPs Delayed 100% Better than w.t. CP-MR
CPE50Q VLPs (long rods) Delayed 96–99% Better than w.t. CP-MR
CPT28Wf No ordered aggregates No 0% No protection
CPD77K VLPs No 0% No protection
CPE50D VLPs (long rods) No 90–97% No protection
a Effect of each mutation on virion assembly was assessed by introducing the mutation in TMV virus (see also Fig. 2).
b Ability of TMV mutants to move systemically in Xanthi-nn. Virus systemic movement was measured by comparing the rate symptoms development on systemic
leaves: Yes=development of symptoms on the systemic leaves similar to that in w.t. TMV inoculated plants (about 8 to 10 days post-inoculation); No=inoculated
plants never developed symptoms on the systemic leaves; Delayed=inoculated plants developed symptoms on the systemic leaves a least 25 to 30 days post-
inoculation.
c CP mutated at one of the above amino acids were expressed in transgenic plants and their ability to provide CP-MR against TMV was measured in transgenic
Xanthi-NN and in transgenic.
d CP mutated at one of the above amino acids were expressed in transgenic plants and their ability to provide CP-MR against TMV was measured in transgenic
Xanthi-nn (Fig. 3).
e Symptoms produced by TMV-CPE50K on systemic leaves of infected N. tabacum Xanthi-nn plants consisted in leaf curling and local lesions formation.
f Bendahmane et al. (1997).
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designed to alter hydrogen bonding patterns between side
chains of adjacent a.a. while preserving the two negative
charges in the axial inter-subunit interface, thus preserving
electrostatic repulsion. However, because Glu has two –CH2
groups whereas Asp has one, mutant CPD77E was expected to
reduce the distance between side chain residues at 50 and 77,
and increase the distance for the mutant CPE50D. Both mutations
were predicted to interfere with the packing and stability of
VLPs. However, both mutations resulted in the formation of
long VLPs, indicating that the protein has greater aggregation
potential than w.t. CP, and was not limited to the length of viral
RNA (Fig. 2, panels G,H).
Type 2 substitution mutants E50Q or D77N were expected to
remove the repulsive inter-subunit charges without altering
side-chain hydrogen bonding. TMV-CPD77N produced open
disks and short stacks of disks in a non-helical structure, while
TMV-CPE50Q produced, as expected, long aggregates of CP
(i.e., VLPs) (Fig. 2, panels A,B).
Type 3 substitution mutants CPE50M and CPD77A are predicted
to remove the repulsive inter-subunit charge and alter side-chain
hydrogen bonding patterns. EM analysis of leaf extracts from
plants infected with TMV-CPE50M showed the presence of
virion-like helical rods that are similar to those of the w.t. virus.
However, particles formed by CPD77A were flexuous and
significantly shorter than those of w.t. TMV (Fig. 2, panels I,J).
Type 4 substitution mutants E50R, E50K, D77R or D77K
are predicted to alter the electrostatic repulsion site and induce
inter-subunit salt-bridges that are expected to stabilize inter-
subunit interactions and thus enhance the stability of the CPhelical structure in virions and VLPs. Arg substitution mutants,
TMV-CPE50R and TMV-CPD77R, as expected, produced very
long VLPs (Fig. 2, panels E,F), while the Lys mutants TMV-
CPE50K and TMV-CPD77K produced VLPs of shorter length
than the Arg mutants (Fig. 2, panels C,D). The local structural
changes introduced by differences in side chains of these basic
amino acids may be responsible for differences in the
aggregation of the mutant CPs. The side chain of Lys is
hydrophobic, due to the four methylene groups and an amino
group, whereas the Arg side chain consists of three hydrophobic
methylene groups and the strongly basic gamma-guanido
group. The gamma-guanido group of Arg and the amino
group of Lys possess different ionization properties and positive
charge distribution. VLPs formed by CPE50K always co-purified
with aggregates of material of unknown nature, presumably as a
consequence of the mutation (Fig. 2, panel C).
In order to determine whether mutant CPs form infectious
virions we determined the ability of TMV carrying mutant CP to
cause rapid systemic infection in Nicotiana tabacum Xanthi-nn.
All mutant viruses, except TMV-CPE50D and TMV-CPD77K,
systemically infected N. tabacum Xanthi-nn, at rates similar to,
or slower than, w.t. TMV. (Table 1). Plants inoculated with
TMV-CPE50K, TMV-CPE50M, TMV-CPD77E or TMV-CPD77R
developed systemic symptoms by 8 to 10 dpi, similar to plants
inoculated with w.t. TMV. Therefore, the particles formed by
these mutant CPs are presumed to assemble with vRNA to
provide systemic infection. Plants inoculated with TMV-
CPE50R, TMV-CPE50Q, TMV-CPD77A or TMV-CPD77N devel-
oped symptoms after 25 dpi. Therefore, the infectious particles
formed by these mutant CPs is presumed to be of low efficiency.
Fig. 2. Electron-microscopic analysis of assembled VLPs from N. tabacum plants infected with TMVmutated at amino acid E50 (TMV-CPE50Q, TMV-CPE50K, TMV-
CPE50R, TMV-CPE50D, TMV-CPE50M) or at amino acid D77 (TMV-CPD77N, TMV-CPD77K, TMV-CPD77R, TMV-CPD77E, TMV-CPD77A) or w.t. (TMV-U1). The
samples were negatively stained and analyzed at a magnification of 39,000. The bar represents 100 nm.
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Fig. 3. Resistance of transgenic plant lines that producemutant CPs to systemic infection by TMV. Protection assay for TMVinfection in transgenicN. tabacumXanthi-
nn plants expressing wt CP (line 3646) or CP carrying mutations at amino acids Asp77 or Glu50. The plants were inoculated with the TMV-U1 virus (0.1 mg/ml), and
disease development was scored as the percentage of plants that exhibit symptoms on upper leaves and accumulation of TMV in the systemic leaves was measured by
ELISA using anti-CP antibody. ELISAwas performed on samples from 10 plants for each line, as described (Bendahmane et al., 1997).
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formation and non-vascular systemic spread. The delay in
systemic infection may also be due to reduced cell-to-cell
movement of viral RNA as observed with mutant CPT42W
(Bendahmane et al., 2002).
Effects of mutations on CP-MP in transgenic plants
Transgenic tobacco plants that express CP genes encoding
mutations at E50 or D77 residues were developed. At least five
independent transgenic lines were selected for each mutant
based on accumulation of CP equivalent to accumulation of w.t.
CP in N. tabacum Xanthi-nn line 3646 (Powell-Abel et al.,
1986), and N. tabacum Xanthi-NN line 748 (Nelson et al.,
1987). CP-MR against TMV infection was assayed in homo-
zygous transgenic lines and compared to CP-MR in lines 3646
and 748. TMV was applied at 0.1 μg/ml; this produced a mean
of ∼80 local lesions per leaf on non-transgenic N. tabacum
Xanthi-NN plants. We present the results of experiments with
selected lines for each CP mutant; the data were consistent
amongst the lines of each CP mutant tested.
CP-MR in Xanthi-nn transgenic lines
The percentage of Xanthi-nn plants that developed systemic
disease symptoms were scored from 7 dpi, averaged, and
compared with non-transgenic plants (0% protection) and plant
line 3646. As shown in Fig. 3, we observed three levels of
protection.
(1) Transgenic lines accumulating CPE50D or CPD77K (e.g.,
plant lines e and j, respectively) developed disease symp-
toms that were not different from non-transgenic plants.
In these lines the onset and severity of disease symptoms
and virus accumulation in upper systemically infected
leaves were similar to non-transgenic plants (as analyzed
in ELISA using anti-CP antibody; data not presented).(2) Transgenic lines accumulating CPE50K, CPE50R or CPD77N
(e.g., lines a, b and c, respectively) exhibited levels of
CP-MR similar to that provided by w.t. CP in line 3646.
(3) Plant lines accumulating CPE50Q (line a), CPE50M (line d),
CPD77A (line a), CPD77E (line h) or CPD77R (line c) did not
develop symptoms when inoculated with 0.1 μg/ml of
virus, whereas line 3646 showed a delay in symptom
appearance. Lines nn-CPE50M, nn-CPD77E and nn-CPD77R
did not contain detectable virus in upper leaves at 23 dpi,
based on ELISA. Lines nn-CPE50Q and nn-CPD77A
showed very mild symptoms of infection and virus accu-
mulation in the systemic leaves at 23 dpi, but provided
higher protection to TMV infection than line 3646.
CP-MR in Xanthi-NN transgenic lines
Transgenic Xanthi-NN plants which accumulated each of the
mutant CPs were also developed, and five lines that accumulated
CP levels equivalent to those in plant line 748 (contains w.t. CP)
were selected for further study. Plants were inoculated with
TMV at an inoculum concentration of 0.1 μg/ml, and the num-
bers of local necrotic lesions were determined, averaged, and
compared with the number of lesions produced on non-trans-
genic plants (0% protection) and on line 748 plants (Table 1).
Little or no protection was exhibited in NN-CPD77K lines and
each plant line carrying this CP was equally as susceptible to
infection as non-transgenic Xanthi-NN plants. This result was
expected since CPD77K did not provide protection in Xanthi-nn
plants. Xanthi-NN plants expressing all other mutant CPs
(except for CPE50D) provided high levels of protection to TMV
infection. However, there was not strong agreement between
levels of protection in Xanthi-NN and Xanthi-nn transgenic
lines. Based on these results, we grouped mutants into five
classes of protection:
(1) Mutants CPE50R and CPD77N provided protection equi-
valent to that provided by w.t. CP in Xanthi-nn lines,
Fig. 4. Accumulation of CP (A), MP (B) and replicase (C) proteins in BY-2
protoplasts non-transgenic or expressing wt CP or mutant CPs. Protoplast were
prepared from transgenic BY-2 cells expressing CPT42W, CPD77K, CPD77R,
CPE50R or CPE50D, and then infected with TMV RNA. Protoplast samples were
harvested at 11, 16, 24, and 36 hpi. The effect of the transgenic CP (mutant or wt)
on the accumulation of the CP, theMR and the replicase of the infecting virus was
assessed using antibodies directed against each of these viral proteins in ELISA
experiments as described (Bendahmane et al., 1997).
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plants.
(2) Mutants CPE50M , CPE50Q , CPD77A , CPD77E provided
equally high levels of protection in Xanthi-nn and Xanthi-
NN transgenic lines and levels of protection stronger than
provided by w.t. CP. Some plant lines were equally as
resistant as plant lines that contain CPT42W (Bendahmane
et al., 1997, 2002).
(3) Mutant CPE50K provided protection equivalent to that
provided by w.t. CP in Xanthi-nn lines, but provided
slightly lower protection in transgenic Xanthi-NN (90%
to 96% compared to 99% protection in line 748).
(4) Mutant CPD77R provided stronger protection than w.t. CP
in Xanthi-nn plants (equivalent to that in line nn-CPT42W;
Bendahmane et al., 1997) and lower protection than w.t.
CP in Xanthi-NN.
(5) Mutant CPE50D provided no protection in Xanthi-nn
plants but provided a high level of protection in Xanthi-
NN.
CP-MR in transgenic BY-2 protoplasts
Earlier studies conducted in BY-2 protoplasts revealed that
expression of CPT42W reduced accumulation of MP and
consequently reduced the formation of VRCs (virus replication
complexes; Bendahmane et al., 2002; Asurmendi et al., 2004).
To characterize virus replication in the mutant lines we followed
the accumulation of replicase (Rep), MP and CP by ELISA
following infection of protoplasts from BY-2 cells lines after
inoculation with TMV RNA. The mutant CPs selected for this
study represented different structural characteristics represented
by the grouping described above. Lines BY-CPT42W and BY-CP
(w.t. CP) were included as controls and results are similar to
those reported by Bendahmane et al. (2002). Protoplasts of cell
lines BY-CPE50D, BY-CPE50R, BY-CPD77K, and BY-CPD77R
were infected and aliquots were collected after 11, 16, 24 and
36 hours post-infection (hpi): data are presented in Fig. 4.
Cell lines BY-CPE50R and BY-CPD77K showed a similar
pattern of accumulation of rep, MP and CP as the BY-CP line. In
these lines the level of MP was significantly greater than in the
non-transgenic line; similar results were observed with the level
of replicase although the differences relative to the non-
transgenic cell line were not as great as with MP. The amount of
CP was greater in these cell lines when compared with the non-
transgenic line in contrast with the results in BY-CP, which was
not significantly different from the non-transgenic cell line.
In contrast infection of protoplasts from BY-CPD77R was
similar to infection of cell line BY-CPT42W. These two lines
show a marked decrease of all three viral proteins when
compared with the non-transgenic line, indicating reduction in
virus replication (Bendahmane et al., 2002). The results
observed in cell line BY-CPE50D are more difficult to explain,
as replication in this line is not as widely different than the non-
transgenic line except at 36 hpi. It is worth noting that BY-
CPE50D is the most different line within the CPT42W group with
regard to accumulation of MP:GFP (see below). The accumula-
tion of MP is indicative of significant virus replication but may
indicate that regulation of MP production late in replicationdoes not occur in the presence of CPE50D. This is also the only
mutant that provides high level of CP-MR in Xanthi-NN and
low protection on the systemic host (Table 1).
Effect of mutant CPs on MP accumulation
We showed in earlier studies that CPT42W interferes with cell
to cell movement by directly affecting MP accumulation and/or
function (Bendahmane et al., 2002). Glu50 is located on the RS
alpha-helix of the CP, as is Thr42. Furthermore, ionic
interactions between Glu50 and Asp77 occur in the same
plane as does Thr42, i.e., in the axial interaction between two
juxtaposed CP subunits. We therefore analyzed the effect of
each mutation at Glu50 and 4 of the 5 mutations at Asp77 on
MP:GFP fusion protein accumulation during infection to
determine if changes in CP structure will affect accumulation
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transgenic BY2 cells that express mutant or w.t. CP were
infected with TMV-MP:GFP and the accumulation of MP:GFP
was followed by fluorescence microscopy of each cell line at
10, 16, 24 and 36 hpi. Since infection with TMV RNA over-
comes CP-MR (Powell-Abel et al., 1986; Register and Beachy,
1988) we achieved a high proportion of infected protoplasts in
these studies.
In non-transgenic BY2 cells infected with TMV-MP:GFP,
the MP:GFP fusion protein accumulates in unique patterns at
different times during the infection cycle (Heinlein et al., 1995).
For the present study, the patterns of accumulation of MP:GFP
can be grouped in three stages that reflect early, mid, and late
stages of infection (Fig. 5A). The results of the studies are
presented in Fig. 5B and, as shown, the progression of accu-
mulation of MP:GFP follows three patterns into which each CP
mutant can be placed.
The first group of mutant CPs comprises mutations at residue
Glu50, e.g., CPE50K, CPE50M and CPE50R. Expression of these
mutant CPs have positive effects on MP:GFP accumulation that
are similar to, but not identical with, results previously reported
for w.t. CP (Bendahmane et al., 2002). In this group a high
percentage of infected cells accumulate large fluorescent bodies
that contain MP:GFP (such bodies are known to be virus
replication complexes, VRCs; Kawakami et al., 2004) through-
out the infection period 0–36 hpi. This result indicates that in
these protoplasts VRCs continue to produce and accumulate
MP:GFP or that the transition of MP:GFP to microtubules or
degradation is negatively affected in these infections than in
wild-type protoplasts. We conclude that MP:GFP continues to
accumulate throughout infection in these cells; this is in
agreement with data in Fig. 4.
Group 2 includes cell lines producing CP mutants that do not
have an effect on accumulation of MP:GFP; in these cell lines,
MP-containing fluorescent structures accumulated as in infected
non-transgenic BY2 protoplasts. In this group infection
proceeds through the early and mid stages of infection in a
now-familiar pattern (described by Bendahmane et al., 2002)
and by late stages (36 hpi) the MP:GFP is associated with
microtubules and relatively small fluorescent bodies. This
group includes CPD77A, CPD77E, CPD77N (all Asp77 mutantsFig. 5. Effect of mutant CPs expressed in transgenic BY2 cells on MP:GFP
following TMV-MP:GFP infection. (A) Patterns of accumulation of MP:GFP in
BY-2 protoplasts inoculated with TMV-MP:GFP as described by Heinlein et al.
(1995). Protoplasts were inoculated with TMV-MP:GFP RNA, and the
accumulation of MP:GFP was analyzed by fluorescence microscopy. Pictures
were taken at 12, 15, and 24 hpi corresponding to early, mid and late stages of
infection by TMV, respectively. MP:GFP patterns found at each stage are
presented. (B) Quantification of the presence of each of the six patterns (above)
of MP:GFP accumulation during TMV–MP:GFP infection in protoplast
expressing mutant CPs at 10, 16, 24 and 36 hpi. The presence of each pattern
was normalized for the total number of cells counted per point and expressed as
a percent. The three groups of mutants CP with respect to their effect on MP
accumulation are presented: group (1) CP mutants with positive effects on MP
accumulation similar to w.t. CP; group (2) CP mutants that lost the positive
effect of w.t. CP on MP accumulation patterns; group (3) CP mutants that
acquired negative effects on accumulation of MP.except CPD77R). We conclude that these mutants do not affect
the production or accumulation of fluorescent MP:GFP-con-
taining bodies in a positive or negative manner. Nevertheless,
these CPs provide high levels of CP-MR in local lesion and
systemic hosts (Table 1 and Fig. 3).
The third group of CP mutants includes CPE50D, CPE50Q and
CPD77R, each of which has a negative effect on MP:GFP
accumulation similar to the effect of CPT42W (Bendahmane et
al., 2002). In protoplasts of cell lines that contain these mutants,
MP:GFP accumulated in small bodies similar to those produced
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these cells lines produced very few large VRCs and very few
cells proceeded to mid and late stages of infection. The data are
in agreement with results of studies described in Fig. 4 showing
that CPT42W , CPE50D and CPD77R restrict production and/or
accumulation of MP.
Discussion
Earlier studies have shown that CP-MR against tobamo-
viruses is provided by accumulation of transgenic CP. Using
mesophyll protoplasts from non-transgenic as well as from
transgenic plants expressing w.t. CP, previous studies demons-
trated inhibition of disassembly of TMV in cells expressing
the CP (reviewed by Bendahmane and Beachy, 1999). We
also showed a strong positive correlation between the ability
of transgenic CP to self-aggregate to form VLPs and CP-MR
(Bendahmane et al., 1997). Recently, we provided evidence
that protection against CP-MR in this system is the cumu-
lative effect of interference by transgenic CP with virus
disassembly and accumulation of MP during virus infection.
The latter effect is evident in a CP mutant CPT42W, and re-
duces cell to cell virus movement of infection (Bendahmane
et al., 2002).
To further characterize the mechanism of CP-MR we gene-
rated additional mutations in TMV CPs, and selected the site at
the electrostatic repulsion site formed by Glu50 and Asp77
residues in adjacent subunits in the quaternary structure. Repul-
sion of subunits is apparently prevented by binding of divalent
cations at this site (Namba and Stubbs, 1986), thus enabling
assembly of virions and VLPs. Alterations in virion stability
that take place in virus disassembly initiates infection and
indicates a stability-switching mechanism that can respond to
subtle changes in the surrounding environment (Caspar, 1963;
Caspar and Namba, 1990). We generated mutants at each of
these amino acid residues in order to interfere with Glu50–
Asp77 interactions. Glu50 and Asp77 residues are located on
the RS and RR helices within the CP three-dimensional struc-
ture, respectively (Fig. 1). The objective was to remove this
electrostatic repulsion site and increase the stability of
interactions between axially adjacent CPs in the quaternary,
but not the ternary structure of CP. As predicted, mutations
affecting this site of inter-subunits interactions did affect the
normal assembly of virions. Most mutant CPs formed long and/
or flexuous VLPs, some of which are formed by stacked discs
(Fig. 2).
We observed a variety of effects of the mutations on CP-MR
in transgenic N. tabacum plants. CPD77K did not provide
resistance to TMV infection in transgenic Xanthi-NN or Xanthi-
nn. This result was unanticipated since CPD77K can assemble to
VLPs. A possible explanation for the lack of CP-MR comes
from the electron microscopy analysis of TMV-CPD77K VLP,
which shows that the CPD77K is associated with unknown debris
in plant extracts. This association may interfere with CP-MR by
this mutant CP.
In the local lesion host Xanthi-NN, transgenic plants
expressing CPE50D provided 90% to 97% resistance to TMVinfection. Resistance to infection per se (reflected in resistance
in the local lesion host) was anticipated since CPE50D produces
VLPs. In contrast this mutant conferred no CP-MR in the
systemic host. The latter result was unexpected since CPE50D
reduced the production of MP and accumulation of MP:GFP in
infected protoplasts (Figs. 4 and 5), conditions that would
reduce cell–cell spread. However, a closer analysis of data in
Fig. 5 (Group 3) revealed that in cell line BY-CPE50D there
were higher numbers of large fluorescent bodies (VRCs) than
in other cell lines in this group; this may increasing the
likelihood of systemic infection. This result could explain the
observation that resistance in these plant lines that contain
CPE50D gave high levels of CP-MR in some experiments and
not in others. This is the only mutant in which variable results
were observed.
CPD77N provides protection similar to w.t. CP in Xanthi-nn
(line 3646) and higher protection than w.t. CP protection in
Xanthi-NN (line 748). The high stability of VLPs produced by
TMV-CPD77N indicates that CPD77N interferes with virus
disassembly and provides CP-MR equivalent to that provided
by w.t. CP. In BY-CPD77N cells the number of VRCs produced
during mid-stage of infection is lower than in non-transgenic
cells and significantly less than in BY-CP cells following
infection with TMV-MP:GFP. Indeed, placing this mutant in
either Group 1 or group 3 was not a clear decision. The negative
effects of CPD77N on VRC production may be at the origin of
the high resistance in the local lesion host NN-CPD77N.
Mutants CPE50Q, CPD77R, CPD77E and CPD77A provided
very high levels of protection to TMV in transgenic Xanthi-nn
as well as Xanthi-NN plants. Protection levels were similar to
protection provided by CPT42W (Bendahmane et al., 1997,
2002). Moreover, these mutant CPs reduced MP:GFP accumu-
lation in infected transgenic BY2 cells. The data are in agree-
ment with results of other mutants (above) and show that the
cumulative effect of strong interference with virus disassembly
and negative effects on MP accumulation in VRCs are neces-
sary and responsible for high levels of CP-MR to TMV
infection.
Mutant CPE50M behaves like w.t. CP in all aspects studied
here. Virions formed by CPE50M were similar to those of w.t.
TMV and systemic infection in non-transgenic plants was
similar. In transgenic protoplasts that express CPDE50M the
accumulation of MP:GFP following infection was similar to
similar to protoplasts that produce w.t. CP. However, CPE50M
provided higher levels of CP-MR in Xanthi-nn and Xanthi-NN
plants than did w.t. CP. This indicates that CPE50M may act
through combinatorial action that involves interference with
disassembly (as does w.t. CP) and a yet to be determined
interference with infection by the challenge virus, thus
representing another argument for the complexity of CP-MR.
These studies confirm that the role of TMV CP in regulating
multiple steps in virus replication and in CP-MR is complex.
Studies of mutant CPs such as those reported here are likely to
form different conformational forms and intermediates in
quaternary structure that are not characterized (see accompany-
ing work by Asurmendi et al., 2007). Our data suggest that some
of the transgenic conformers and/or intermediates of w.t. and
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regulate virus infection, movement and replication.
Materials and methods
TMV clones
TMV variants harboring the MP tagged with GFP (TMV-
MP:GFP) or the CP tagged with GFP (TMV-CP:GFP) have
been described (Heinlein et al., 1995; Bendahmane et al.,
2002).
Mutant CPs and virus constructs
The TMV CP amino acids Glu50 and Asp77 were mutated to
Asp, Gln, Arg, Lys or Met, and Asp77 was mutated to Glu, Asn,
Arg, Lys or Ala using a PCR-based site-directed mutagenesis
and cloned in the vector pKN2 as described (Bendahmane et al.,
1997). The resulting intermediate plasmids are referred to as,
pCPE50D, pCPE50Q, pCPE50R, pCPE50K, pCPE50M, pCPD77E,
pCPD77N, pCPD77R, pCPD77K, and pCPD77A.
A DraI–KpnI fragment containing the mutated CP gene
(TMV nucleotide 5708 to 6395; Goelet et al., 1982) from the
above plasmids was ligated into an expression cassette that
places each cDNA between the 35S promoter and the nos 3′
terminator. The expression cassettes were then transferred into
the vector pCGN1547 (McBride and Summerfelt, 1990). The
resulting plasmids are referred to as pCG-E50D, pCG-E50K,
pCG-E50M, pCG-E50Q, pCG-E50R, pCG-D77A, pCG-D77E,
pCG-D77K, pCG-D77N or pCG-D77R.
cDNA clones harboring the mutant CPs from which
infectious TMV RNA is produced were constructed by
replacing the CP gene in the wild type TMV cDNA (U3/12-4;
Holt and Beachy, 1991) with the mutant CP as described in
Bendahmane et al. (1997). Plasmids thus produced are referred
to as pTMV-CPE50D, pTMV-CPE50Q, pTMV-CPE50R, pTMV-
CPE50K, pTMV-CPE50M, pTMV-CPD77E, pTMV-CPD77N,
pTMV-CPD77R, pTMV-CPD77K, and pTMV-CPD77A.
Construction and analysis of transgenic plants
The plasmids pCG-E50D, pCG-E50K, pCG-E50M, pCG-
E50Q, pCG-E50R, pCG-D77A, pCG-D77E, pCG-D77K, pCG-
D77N or pCG-D77R were used to produce transgenic N.
tabacum Xanthi-NN (a local lesion host of TMV) and Xanthi-
nn plants (a systemic host of TMV) via Agrobacterium
tumefaciens (Horsch et al., 1985). The regenerated kanamy-
cin-resistant plants (kanr) were screened for CP accumulation
using the polyclonal rabbit anti-TMV coat protein antibody in
Western immunoblot assays as described previously (Bend-
ahmane et al., 1997). Plant lines are referred to as NN- or nn-
CPE50D, CPE50K, CPE50M, CPE50Q, CPE50R, CPD77A, CPD77E,
CPD77K, CPD77N, CPD77R, respectively. Plants that accumulated
CP were self-pollinated and R1 plants and homozygous plants
were identified and their R2 plant seedlings were used for all
studies. Plant lines from amongst more than 15 lines containing
each construct were selected for further study on the basis ofaccumulation of equivalent amounts of CP as determined by
quantitative Western immunoblot assays.
Construction and analysis of transgenic BY2 cell lines
The plasmids pCG-E50D, pCG-E50K, pCG-E50M, pCG-
E50Q, pCG-E50R, pCG-D77A, pCG-D77E, pCG-D77K, pCG-
D77N or pCG-D77R were used to transform the tobacco BY2
cell line using A. tumefaciens-mediated transformation. The
regenerated kanamycin-resistant cell lines (kanr) were screened
for CP accumulation using the polyclonal rabbit anti-TMV coat
protein antibody in Western immunoblot assay as above. Cell
lines with high levels of CP were used for further studies. These
lines are referred to as BY-CPE50D, BY-CPE50K, BY-CPE50M,
BY-CPE50Q, BY-CPE50R, BY-CPD77A, BY-CPD77E, BY-
CPD77K, BY-CPD77N or BY-CPD77R, respectively. Cell lines
selected for further study contained equivalent amounts of
mutant or wild type CP as determined by Western immunoblot
assays.
In vitro synthesis of viral RNA and plant and BY2 protoplast
inoculation
In vitro transcribed full-length viral RNAs were generated
from w.t. and mutant TMV cDNA clones and used to inoculate
plants as previously described (Bendahmane et al., 1997).
Protoplasts were prepared from BY-2 suspension cell cultures,
inoculated with in vitro transcribed viral RNA via electropora-
tion, as described (Watanabe et al., 1987, Bendahmane et al.,
2002). Infected plants and protoplasts were analyzed by
fluorescence and laser scanning confocal microscopy as
described (Bendahmane et al., 2002).
Purification and analysis of virus particles from infected plants
Wild type and mutant viruses were purified from infected
plant leaves as described previously (Asselin and Zaitlin, 1978;
Bendahmane et al., 1997).
Electron microscopy: Purified viruses at concentrations of 10
to 100 μg/ml were applied to carbon coated copper EM grids
and then negatively stained with a 2% uranyl acetate solution
for 2 min. Grids were allowed to dry prior examination on a
Phillips CM100 electron microscope at 39,000×.
Assays for CP-MR
Transgenic N. tabacumXanthi-NN and Xanthi-nn plant lines
expressing the mutant CPs or wt CP [lines 748 (Nelson et al.,
1987) and 3646 (Powell-Abel et al., 1986)] were grown in a
greenhouse without supplemental light and with temperatures
ranging from 24 °C to 26 °C during the day and 20 °C to 21 °C
during the night. At 4 weeks after transplanting, the plants were
inoculated on a single leaf previously dusted with carborundum
(320 GRIT, Fisher Scientific). TMV diluted to concentrations of
0.1 μg/ml in 20 mM NaHPO4, pH 7, was used as inoculum. On
Xanthi-NN transgenic lines, the relative levels of protection
conferred by the different mutant CPs were scored by comparing
116 M. Bendahmane et al. / Virology 366 (2007) 107–116the numbers of necrotic lesions on the transgenic lines versus
non-transgenic plants. The relative degree of systemic protection
was scored by monitoring the appearance of disease symptoms
and virus accumulation in the upper non-inoculated leaves.
Virus accumulation was quantified using an indirect sandwich
ELISA as previously described (Bendahmane et al., 1997).
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